N-butylscopolammonium bromide causes fewer side effects than atropine when assessing bronchoconstriction reversibility in horses with heaves.

Summary

# Editorial Summary When evaluating airway reversibility in horses with recurrent airway obstruction (RAO/heaves), anticholinergic bronchodilators provide valuable diagnostic information, but atropine's systemic side effects—including tachycardia, mydriasis, and reduced gut motility—can complicate both the clinical assessment and the patient's recovery. De Lagarde and colleagues compared atropine with N-butylscopolammonium bromide (NBB), a quaternary ammonium anticholinergic compound, in a controlled study examining bronchoconstriction reversibility in RAO-affected horses. NBB proved significantly more selective for airway smooth muscle, producing comparable bronchodilatory effects to atropine whilst generating fewer systemic adverse effects, particularly regarding heart rate elevation and ocular changes. These findings suggest NBB could offer a safer alternative for diagnostic bronchoprovocation testing and therapeutic assessment in heaves cases, allowing clinicians to establish reversibility without the complications that might mask or confound clinical signs. For practitioners managing RAO horses, adopting NBB where available could improve diagnostic accuracy and animal welfare during airway function assessments.

Read the full abstract on PubMed

Key Findings

• •N-butylscopolammonium bromide (NBB) is an effective anticholinergic bronchodilator for assessing bronchoconstriction reversibility in horses with heaves
• •NBB causes fewer side effects than atropine while maintaining bronchodilatory efficacy
• •NBB may be a safer alternative to atropine for airway assessment in equine respiratory disease

Conditions Studied

Tags